# US 2024/0189221 A1 · Methods and formulations for treating vascular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189221 A1
- Document ID: US20240189221A1
- Status: Published application
- Kind: A1
- Application number: 18/348,954
- Filed: 2023-07-07
- Published: 2024-06-13
- Earliest claimed: 2015-12-10
- Assignees: Endoperfusion Solutions, LLC
- Applicants: Endoperfusion Solutions, LLC
- Inventors: Jaipal SINGH; Yan XIN; Osama ABOUL-MAGD
- Web page: https://patentgrep.com/patent/US20240189221A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61L 29/08: Materials for coatings
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61M 25/10: Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00})
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61L 2300/434: of enzymes
- A61L 2300/606: Coatings
- A61L 2300/626: Liposomes, micelles, vesicles
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- A61M 2025/105: {having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Devices and methods for treating a vascular disease in a subject are disclosed that involve acute administration of a statin locally to a diseased segment of a blood vessel in the subject.

## Claims

### Claim 1

A method for treating a vascular disease in a subject in need thereof, comprising acutely administering a statin locally to a diseased segment of a blood vessel in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the statin comprises cerivastatin, a cerivastatin analog, or a pharmaceutically acceptable salt, prodrug, clathrate, or solvate thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the statin is administered in an effective amount to induce DDAH2 gene expression in vascular endothelial cells in the diseased segment of the blood vessel in the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the statin is administered in an effective amount to decrease CCR2 gene expression in vascular endothelial cells in the diseased segment of the blood vessel in the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the statin is administered at a dosage of from 1 ng/mm diseased segment of the blood vessel to 10 μg/mm diseased segment of the blood vessel.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein acute administration of the statin comprises delivery of at least 80% of a dosage of the statin to the diseased segment within 5 minutes.

### Claim 8 (depends on 7)

The method of claim 7, wherein acute administration of the statin comprises delivery of at least 90% of the dosage of the statin to the diseased segment within 1 minute.

### Claim 9 (depends on 1)

The method of claim 1, wherein the vascular disease is selected from the group consisting of atherosclerosis, transplant atherosclerosis, vein-graft atherosclerosis, thrombosis, restenosis, stent restenosis, and angioplasty restenosis.

### Claim 10 (depends on 9)

The method of claim 9, wherein the vascular disease is stent restenosis.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the statin is administered percutaneously to the diseased segment of the blood vessel.

### Claim 14 (depends on 13)

The method of claim 13, wherein the statin is administered by a drug-coated catheter balloon.

### Claim 15 (depends on 13)

The method of claim 13, wherein the statin is administered by a drug-eluting catheter balloon.

### Claim 16 (depends on 13)

The method of claim 13, wherein the statin is administered by an injection feature affixed to the surface of a catheter balloon.

### Claim 17 (depends on 1)

The method of claim 1, wherein acute administration of the statin locally to a diseased segment of a blood vessel in the subject decreases the rate of formation of a lactone metabolite of the statin relative to oral administration of an equivalent dosage of the statin.

### Claim 18 (depends on 1)

The method of claim 1, wherein the statin is administered as a pharmaceutical formulation comprising the statin and a lipid-based carrier.

### Claim 19 (depends on 18)

The method of claim 18, wherein the lipid-based carrier comprises lipid-based particles.

### Claim 20 (depends on 19)

The method of claim 19, wherein the lipid-based particles have an average particle size of from 1 nm to 200 nm, as determined by dynamic light scattering.

### Claim 21

(canceled)

### Claim 22 (depends on 19)

The method of claim 19, wherein the lipid-based particles comprise liposomes or lipid micelles.

### Claim 23

(canceled)

### Claim 24

A kit comprising a drug-eluting balloon catheter and a pharmaceutical composition comprising a therapeutically effective amount of the statin to treat a vascular disease in a subject in need thereof when administered locally to a diseased segment of a blood vessel in the subject via the drug-eluting balloon catheter.

### Claim at position 25

25-32. (canceled)

### Claim 33

A catheter balloon completely or partially coated with a statin, wherein a therapeutically effective amount of the statin is released and/or bioavailable of when the balloon is inflated intraluminally.

### Claim at position 27

34-40. (canceled)

### Claim 41

A pharmaceutical formulation comprising a statin encapsulated in a lipid-based particles, wherein the statin is present in therapeutically effective amount to treat a vascular disease in a subject in need thereof when administered locally to a diseased segment of a blood vessel in the subject.

### Claim at position 29

42-45. (canceled)
